Series B

A new platform launches to connect accessible tech startups with users and investors, aiming to unify a fragmented but powerful innovation ecosystem.

A new benchmark shows top AI voice tools fail in non-English languages, challenging billion-dollar deployments and exposing deep-rooted linguistic bias.

The new CROSSx Disclosed platform combines Wall Street-style trading relationships with blazing speed, aiming to lower costs and risks for institutions.

By rethinking a 50-year-old component, Aqua Membranes is poised to revolutionize water treatment and contend for the $119M XPRIZE Water Scarcity prize.

As its oesophageal cancer vaccine enters trials, Infinitopes hires a top CSO with a track record of bringing breakthrough therapies to market.

As investors flee to gold, a new report highlights top IRA providers. But what are the real risks and rewards of moving your 401k into precious metals?

A health plan reports 13% lower costs and 90% satisfaction by integrating care, not just insuring it. Can this model fix employer healthcare?

Facing financial pressures, the biotech divests a key cancer program, repays debt, and now explores all options to maximize value for its remaining pipeline.

As it nears $10B in assets, investment firm Disruptive hires a top tech advisor, signaling a new phase of strategic growth for its unique investment model.

Forethought founder Deon Nicholas unveils Espa, an AI executive assistant that executes tasks, aiming to democratize productivity for all.

Fueled by a $100M R&D investment, Chinese beauty giant Yatsen is leading a market shift from price wars to scientific innovation, winning global consumers.

Three industry titans launch AlphaDrive, a $100M fund blending VC and private equity to back the next generation of Israeli Cyber-AI startups.

A new $50M fund unites venture capital with Canada's top cancer charities, aiming to fast-track lab discoveries into life-saving patient treatments.

With $255M raised, Diagonal Therapeutics brings on a seasoned CFO to advance its novel antibody treatments for rare genetic diseases into the clinic.

The clinical-stage biotech adds seasoned veterans from Eli Lilly and Iovance to accelerate its promising DNA Damage Response pipeline toward commercialization.

UTime's latest capital raise is a fraction of its needs. We dive into the firm's mounting losses, stock dilution, and what this means for its future.

Medcura adds a Johnson & Johnson heavyweight to its board, aiming to disrupt the surgical hemostasis market with its FDA-designated breakthrough gel, LifeGel.

AI-native firm Norm Law adds veteran tax and fund formation counsel, deepening its tech-driven challenge to the traditional legal services model for investors.

A new AI platform promises to fix billions in revenue loss from complex cardiac coding, but will it empower or replace human experts in the process?

TRexBio has dosed the first patient in a new trial for its novel drug, TRB-061, which aims to rebalance the immune system to treat atopic dermatitis.